| Reducing the carbon impact of inhalers across the North of England |
Prescribing bulletin |
September 2021 |
| Omalizumab and dupilumab for chronic rhinosinusitis with nasal polyps |
Evaluation report |
September 2021 |
| Respiratory System |
Prescribing Data Report |
January 2022 |
| Inhaler Carbon Impact Assessment Tool |
Prescribing Data Report |
November 2021 |
| Inhaler carbon footprint; significance, focus & action |
Prescribing for Population Health |
January 2021 |
| Comparison of LAMA/LABA inhalers (update February 2021) |
Prescriber Support Tools |
February 2021 |
| Comparison of oscillating positive expiratory pressure devices |
Prescriber Support Tools |
August 2019 |
| Fluticasone, umeclidinium, and vilanterol (Trelegy Ellipta) for COPD |
New Drug Evaluations |
May 2018 |
